Chenliang Ge | Cardio-oncology | Best Research Article Award

Posted on by Pencis

Mr. Chenliang Ge | Cardio-oncology | Best Research Article Award

The First Affiliated Hospital of Guangxi Medical University | China

Author Profile:

Scopus

Orcid

🫀DR. CHENLIANG GE, MD, PHD – A PIONEERING CARDIOVASCULAR RESEARCHER & CLINICIAN

Dr. Chenliang Ge is an accomplished physician-scientist whose work bridges clinical cardiology and data-driven medical research. With a robust foundation in both molecular mechanisms and large-scale epidemiological analysis, he continues to redefine the frontiers of cardiovascular science and patient care.

🎓 EARLY ACADEMIC PURSUITS

Dr. Ge began his academic journey with a Bachelor of Medicine, Bachelor of Surgery (MBBS) from Nanhua University, Hengyang (2008–2013). His passion for cardiology led him to pursue a Master of Science in Cardiology (2013–2016) from the same university. Advancing his specialization, he earned a PhD in Cardiology from Guangxi Medical University, Nanning, China (2019–2022), where he laid the groundwork for his breakthrough research in atrial fibrillation and molecular cardiology.

👨‍⚕️ PROFESSIONAL ENDEAVORS

Since 2016, Dr. Ge has served as an Attending Physician at the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China. In this role, he:

  • Diagnoses and manages complex cardiovascular conditions.

  • Specializes in radiofrequency ablation procedures for atrial fibrillation (AF) and supraventricular tachycardia.

  • Combines clinical acumen with cutting-edge research to enhance patient outcomes.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIO-ONCOLOGY

Dr. Ge’s research interests lie at the confluence of cardiology, artificial intelligence, and epidemiology. His contributions span three major domains:

1. EPIDEMIOLOGICAL INSIGHTS INTO CVD AND SYSTEMIC HEALTH

  • Cardiovascular Disease and Cancer Mortality (2024): Identified heart failure as a standalone risk factor for cancer mortality using NHANES data.

  • Physical Activity in Hypertension (2024): Demonstrated the life-extending benefits of moderate-intensity exercise in hypertensive patients.

2. MOLECULAR MECHANISMS IN ARRHYTHMIAS

  • PhD Dissertation: Uncovered the role of TLR4 and NLRP3 inflammasome activation in atrial fibrillation.

  • Key Finding (2022): TLR4 silencing reduced atrial fibrosis and AF susceptibility by downregulating NLRP3-TGF-β pathways, suggesting promising therapeutic targets.

3. TECHNOLOGY-DRIVEN DIAGNOSIS AND PROGNOSIS

  • Echocardiographic Risk Stratification (2024): Developed an automated tool using echocardiography to predict left atrial low-voltage areas (LA-LVAs).

  • Gene Signature for NIDCM Prognosis (2020): Created a two-gene model to predict survival and ventricular arrhythmias in non-ischemic dilated cardiomyopathy (NIDCM).

🧠 TECHNICAL AND CLINICAL EXPERTISE

RESEARCH SKILLS:

  • Molecular biology techniques: PCR, Western blotting, immunohistochemistry.

  • Confocal microscopy and in vivo/in vitro models.

  • Epidemiological analysis using NHANES and UK Biobank datasets.

  • Data analytics: Python, R, SPSS; Machine learning and deep learning.

CLINICAL EXPERTISE:

  • Cardiac electrophysiology and ablation procedures.

  • Echocardiography with tools like Philips Epic 7C and AutoStrain.

  • Risk modeling and survival analysis for personalized cardiac care.

🌍 IMPACT AND INFLUENCE

Dr. Ge's work directly informs both clinical practice and public health policy. By connecting chronic diseases like heart failure and cancer, his findings push for integrated healthcare models. His gene-based and imaging-based diagnostic tools enable precision medicine, allowing for personalized and cost-effective interventions.

📚 ACADEMIC CITES

  • Ge et al., 2020 – Gene Signature in NIDCM

  • Ge et al., 2022 – TLR4 & NLRP3 in Atrial Fibrillation

  • Ge et al., 2024 – Physical Activity in Hypertension & CVD-Cancer Link

  • Chang et al., 2024 – Echocardiographic Risk Stratification (collaborative work)

🚀 LEGACY AND FUTURE CONTRIBUTIONS

With a unique blend of clinical insight and computational proficiency, Dr. Ge is at the forefront of next-generation cardiovascular care. His future directions likely include:

  • Expanding the use of AI in cardiology diagnostics.

  • Further investigating multi-system interactions in chronic diseases.

  • Advocating for preventive cardiology through large-scale data and public health outreach.

His legacy is one of bridging bench-to-bedside translation, ensuring that rigorous research translates into better lives for patients globally.

📑 NOTABLE PUBLICATIONS

"The global burden of high BMI among adolescents between 1990 and 2021" 

Authors: Ge C; Xiong J; Zhu R; Hong Z; Yan He
Journal: Communications medicine
Year: 2025

"Automatic Echocardiographic Assessment of Left Atrial Function for Prediction of Low-Voltage Areas in Non-Valvular Atrial Fibrillation" 

Authors: Shuai Chang; Xiaofeng Zhang; Chenliang Ge; Yanfen Zhong; Decai Zeng; Yongzhi Cai; Tongtong
Journal: International Journal of General Medicine
Year: 2024

"Associations between cardiovascular diseases and cancer mortality: insights from a retrospective cohort analysis of NHANES data" 

Authors: Ge C; Jiang Z; Long B; Lu Q; He Y
Journal: BMC public health
Year: 2024

Cheng Shen | Cardiac Surgery | Best Researcher Award

Posted on by Pencis

Prof. Dr. Cheng Shen | Cardiac Surgery | Best Researcher Award

West China Hospital | China

Author Profile: 

Scopus

Orcid

📘 EARLY ACADEMIC PURSUITS 

Cheng Shen began his academic journey at Kunming Medical University, earning his Bachelor of Medicine in Clinical Medicine in 2011. His passion for clinical excellence and research led him to the West China School of Medicine, Sichuan University, where he pursued a Ph.D. in Thoracic Surgery while simultaneously working as a Resident Doctor and Research Assistant from 2011 to 2017. During this period, he honed his clinical and research acumen, laying a strong foundation for his future contributions to oncology and thoracic surgery.

🩺 PROFESSIONAL ENDEAVORS

Dr. Cheng Shen currently serves as an Attending Physician in the Department of Thoracic Surgery at West China Hospital, Sichuan University. His international academic exposure includes his time as a Visiting Scholar at Yale University (2015–2016) in the Department of Molecular Biophysics and Biochemistry, where he advanced his expertise in molecular mechanisms of DNA repair. This blend of clinical practice and laboratory precision has equipped him to lead cutting-edge investigations in thoracic oncology.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIAC SURGERY

Dr. Shen’s research spans several high-impact domains, including:

  • Targeted Gene Therapy and Immunotherapy

  • Molecular Mechanisms of Cancer Invasion and Metastasis

  • Cell and Tissue Engineering

  • Stem Cell Function and Differentiation

His research during his Yale tenure focused on the mechanism of homology-directed DNA repair, using yeast and human models. He also explored genomic instability in primary lung cancers and conducted studies on cancer-associated fibroblasts in lung adenocarcinoma.

🌐 IMPACT AND INFLUENCE 

Cheng Shen has contributed significantly to the understanding of tumor biology, particularly in thoracic malignancies. His ability to translate complex molecular biology into practical clinical insights makes him a crucial figure in personalized cancer therapy. He has also designed and led several small clinical trials, emphasizing his commitment to bridging the bench-to-bedside gap.

🏅 ACADEMIC CITES AND COLLABORATIONS

While specific citation counts are not provided, his training at Yale University, multiple national-level scholarships, and leadership in clinical trials reflect a robust academic profile. His research work is likely referenced in the fields of genomic instability, lung cancer, and DNA repair mechanisms.

🚀 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Cheng Shen’s future appears poised for further breakthroughs in thoracic cancer treatment and regenerative medicine. As a physician-scientist with deep laboratory roots and clinical experience, he is uniquely positioned to drive innovation in cancer therapy, particularly with emerging gene and cell-based interventions. His trajectory indicates continued leadership in integrative and translational medical research.

🏆 OTHER IMPORTANT AREAS OF EXCELLENCE 

LANGUAGE PROFICIENCY:

  • Advanced in English, having cleared PETS-3, PETS-4, CET-4, and CET-6.

LAB PROFICIENCY:

  • Expertise in PCR, Western Blot, ELISA, Cell Culture, and Signaling Pathway Inhibition.

  • Strong in Animal Models and Transwell Cell Migration assays.

HONORS & SCHOLARSHIPS:

  • State Scholarship Fund (CSC) (2015–2017)

  • National Graduate Scholarships (2012–2014)

  • Full Scholarship from Sichuan University (2011–2016)

  • Multiple Merit Scholarships during undergraduate studies

NOTABLE PUBLICATIONS

"Accuracy of Large Language Models for Literature Screening in Thoracic Surgery: Diagnostic Study"

Authors: ZY Dai, FQ Wang, C Shen, YL Ji, ZY Li, Y Wang, Q Pu
Journal: Journal of Medical Internet Research
Year: 2025

"A combined subsegmentectomy of right S9 + 10b with single direction thoracoscopic surgery"

Authors: C Shen, C Liu
Journal: Journal of Cardiothoracic Surgery
Year: 2024

"Robot-assisted thoracic surgery versus video-assisted thoracic surgery for treatment of patients with thymoma: A systematic review and meta-analysis"

Authors: Shen C, Li J, Li J, Che G
Journal: Thoracic Cancer
Year: 2022

Shuai Wang | Ischemic Stroke | Best Researcher Award

Posted on by Pencis

Mr. Shuai Wang | Ischemic Stroke | Best Researcher Award

Royal College of Surgeons | Ireland

Author Profile:

Scopus

Orcid

🎓 EARLY ACADEMIC PURSUITS

Shuai Wang began his academic journey in the field of pharmacy at Soochow University in Suzhou, Jiangsu Province. He earned his Bachelor of Pharmacy (2015–2019) and continued there for a Master’s degree in Pharmacy (2020–2023). His consistent academic excellence led him to pursue a PhD in Pharmacy at the Royal College of Surgeons in Ireland (2023–Present). His early dedication to the sciences laid the groundwork for a promising career in neuropharmacology.

🧪 PROFESSIONAL ENDEAVORS 

During his time at Soochow University, Shuai Wang was actively involved in numerous cutting-edge research projects under the guidance of Professor Hui-Ling Zhang. His work primarily focused on the molecular mechanisms underlying ischemic stroke and neuroinflammation, combining both in vivo and in vitro methodologies to produce meaningful scientific insights.

He contributed significantly to interdisciplinary research through collaborative pharmacodynamic studies, including:

  • DTIO’s role in promoting brain function recovery post-stroke (2021–2022)

  • VT101’s protective effects against myocardial ischemia/reperfusion injury (2020–2021)

🧬 CONTRIBUTIONS AND RESEARCH FOCUS ON ISCHEMIC STROKE

Wang’s research focus is neuropharmacology, with an emphasis on neuroinflammation, lipid metabolism, and cellular cross-talk following ischemic stroke. One of his landmark projects investigated the VEGFD/VEGFR3 pathway and its regulatory effect on IL-3/IL-3Rα interactions between astrocytes and microglia. His innovative approach used metabolic analysis and dual-model experimentation to explore cellular responses and pharmacological mechanisms.

📈 IMPACT AND INFLUENCE 

Shuai Wang has co-authored influential research papers in high-impact journals, including:

  • VEGFD/VEGFR3 mediates neuroinflammation and lipid metabolism reprogramming after ischemic stroke by regulating IL-3/IL-3Rα crosstalk between astrocytes and microglia.

  • The novel role and anti-inflammatory mechanisms of brain matrilin-3 in ischemic stroke, published in Cell Reports alongside distinguished co-authors.

These publications reflect his deep engagement with pressing medical challenges and his ability to contribute meaningfully to collaborative scientific inquiry.

🏅 ACADEMIC CITES AND RECOGNITIONS 

Wang's academic work has begun to garner citations and recognition within pharmacological and neuroscience communities. In recognition of his academic diligence and research output, he was awarded the Soochow University Master Scholarship consecutively in 2020, 2021, and 2022.

🚀 LEGACY AND FUTURE CONTRIBUTIONS 

Shuai Wang represents the next generation of innovative scientists in the field of neuropharmacology. With a strong academic foundation, extensive research training, and a visionary approach to disease mechanisms and treatment development, he is well-positioned to make future breakthroughs in stroke therapy and neurodegenerative disease research.

As he continues his doctoral research in Ireland, his future contributions are anticipated to shape both the theoretical landscape and clinical applications in neurology and pharmacotherapy.

📑 NOTABLE PUBLICATIONS

"VEGFD/VEGFR3 signaling contributes to the dysfunction of the astrocyte IL-3/microglia IL-3Rα cross-talk and drives neuroinflammation in mouse ischemic stroke"

Authors: Shuai Wang; Yi Guo; Rui-qi Cao; Yong-ming Zhu; Shi-gang Qiao; Hua-ping Du; Yuan Liu; Yuan Xu; Xian-yong Zhou; Lei Sun
Journal: Acta Pharmacologica Sinica
Year: 2025

 

Di-Hua Yu | Cardiopulmonary Resuscitation | Best Researcher Award

Posted on by Pencis

Mr. Di-Hua Yu | Cardiopulmonary Resuscitation | Best Researcher Award

Hubei Provincial Hospital of TCM | China

Author Profile:

Orcid

🎓 EARLY ACADEMIC PURSUITS

Di-Hua Yu laid a solid foundation for his medical and research career at the Hubei University of Chinese Medicine. He earned his Bachelor’s degree (2007–2012) with a stellar GPA of 3.9/4.0, receiving the prestigious First Prize Scholarship 🏅. He continued his academic excellence in his Master’s program (2012–2014), graduating with a GPA of 3.8/4.0 and being named an Outstanding Graduate 🌟. These early achievements highlighted his strong work ethic, deep curiosity, and aptitude for medical research.

💼 PROFESSIONAL ENDEAVORS

Since 2014, Yu has served as a Researcher in the Emergency Department at the Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan 🇨🇳. His role places him at the heart of real-time emergency care, where he applies both traditional Chinese medical knowledge and modern evidence-based practices. His daily work bridges front-line clinical challenges and academic inquiry 📊🩺.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOPULMONARY RESUSCITATION

Yu’s research spans a multidisciplinary range of subjects that combine innovation with tradition:

  • 🏥 Emergency Medical Systems

  • ❤️ Cardiopulmonary Resuscitation

  • 💔 Cardiac Arrest

  • 📈 Statistical Analysis

  • 🤖 Artificial Intelligence in Medicine

His work reflects an evolving research focus that responds to modern healthcare challenges while respecting the insights of traditional Chinese medicine 🧪🌿.

🌐 IMPACT AND INFLUENCE

Di-Hua Yu has made meaningful scholarly contributions through publications such as:

  • “Factors Influencing Resuscitation Outcomes in Obese Out-of-Hospital Cardiac Arrest Patients” – Notfall + Rettungsmedizin 🚨

  • “Research Progress on the Toxicity of Tripterygium Wilfordii and Attenuated Synergistic Approaches” – YIXUE ZONGSHU

  • Multiple clinical studies on integrative therapies using Chinese herbal injections and formulations 🌱💉

These studies provide valuable insights into treatment effectiveness, especially in high-risk or emergency scenarios.

📚 ACADEMIC CITES

Yu’s ORCID profile (🔗 0000-0001-8628-4005) serves as his official research ID. While his presence on global platforms like Google Scholar and ResearchGate is still in development, the quality and diversity of his publications suggest growing academic recognition and future citation potential 📖✨.

🌟 LEGACY AND FUTURE CONTRIBUTIONS

Di-Hua Yu stands out as a forward-thinking medical researcher who blends traditional Eastern practices with modern Western methodologies. With rising global interest in AI-driven medical support systems 🤖 and personalized emergency care, Yu is well-positioned to contribute to:

  • 📡 Smarter Emergency Response Systems

  • 🔍 Data-Based Clinical Decision Tools

  • 🧬 Personalized Resuscitation Strategies

  • 🌏 Global Dialogues on Integrative Medicine

His legacy is expected to lie in fostering collaboration between ancient healing philosophies and next-generation technology 🛠️🌿.

📑NOTABLE PUBLICATIONS

"Factors influencing resuscitation outcomes in obese out-of-hospital cardiac arrest patients"

Authors: Wei-Qing Wang, Ying-Lin Wang, Zheng Zhu, Xiao-Xia Zeng, Gang Li, Di-Hua Yu
Journal: Notfall + Rettungsmedizin
Year: 2025

 

Hadi Emamat | Body Fat Distribution | Best Researcher Award

Posted on by Pencis

Hadi Emamat | Body Fat Distribution | Best Researcher Award

Bushehr University of Medical Sciences | Iran

Author Profile:

🎓 EARLY ACADEMIC PURSUITS

Dr. S.M. Hadi Emamat began his academic journey in the field of Nutrition Sciences at Shahid Beheshti University of Medical Sciences (SBMU), one of Iran's premier institutions. He completed his Bachelor's degree (2007–2011), followed by a Master's (2012–2015) and eventually earned his Ph.D. (2016–2020) in the same field. From the outset, Dr. Emamat demonstrated a strong commitment to exploring how diet influences health and disease, particularly focusing on metabolic and liver conditions.

👨‍🏫 PROFESSIONAL ENDEAVORS

Dr. Emamat currently serves as an Assistant Professor at the Department of Nutritional Sciences, School of Health and Nutrition, Bushehr University of Medical Sciences (BPUMS), Iran. His role encompasses both academic teaching and active research. He imparts knowledge through specialized courses, notably Medical Nutrition Therapy, aiming to train the next generation of nutrition professionals.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON BODY FAT DISTRIBUTION

Dr. Emamat's scientific research is primarily centered on the relationship between nutrition and chronic metabolic disorders. His scholarly work includes:

  • Investigating barberry's effect on cardiovascular risk factors in hypertensive patients for his Ph.D. thesis.

  • Studying the impact of onion consumption on features of nonalcoholic fatty liver disease (NAFLD) in animal models during his Master's research.

His broader research interests include:

  • Nutrition and Non-Alcoholic Fatty Liver Disease (NAFLD)

  • Nutrition and Cardiovascular Disease, particularly vascular function

  • Metabolic Syndrome

  • Nutrition and Gut Microbiota

These studies contribute to a growing body of evidence linking diet with systemic inflammation, blood pressure regulation, lipid profiles, and metabolic health.

🌍 IMPACT AND INFLUENCE

Dr. Emamat's work addresses global public health challenges, such as cardiovascular disease and NAFLD, which are on the rise due to poor dietary habits and sedentary lifestyles. His research provides valuable insights into how traditional foods and natural compounds can serve as functional interventions for chronic conditions. As an educator and investigator, he plays a pivotal role in shaping clinical nutrition strategies in Iran and beyond.

🌱 LEGACY AND FUTURE CONTRIBUTIONS

With a solid foundation in clinical nutrition research and education, Dr. Emamat is well-positioned to make further advances in nutritional interventions for chronic diseases. His continued focus on evidence-based dietary solutions, integration of microbiome science, and public health applications will likely shape both policy and practice in the years ahead. His dedication signals a promising trajectory toward becoming a key figure in translational nutrition science.

📑 NOTABLE PUBLICATIONS

"The association between the visceral to subcutaneous abdominal fat ratio and the risk of cardiovascular diseases: a systematic review" 

Authors: Hadi Emamat, Ali Jamshidi, Akram Farhadi, Hamid Ghalandari, Mohadeseh Ghasemi, Hadith Tangestani
Journal: BMC public health
Year: 2024

"Association of serum 25-hydroxy vitamin D status with cardiometabolic risk factors and total and regional obesity in southern Iran: evidence from the PoCOsteo study" 

Authors: Alireza Nejabat, Hadi Emamat, Sima Afrashteh, Ali Jamshidi, Zahra Jamali, Akram Farhadi, Zahra Talkhabi, Iraj Nabipour, Bagher Larijani, Jörg Spitz
Journal: Scientific Reports
Year: 2024

Yuriy Borshchev | Ischemic-reperfusion injury | Best Researcher Award

Posted on by Pencis

Dr. Yuriy Borshchev | Ischemic-reperfusion injury | Best Researcher Award

Almazov National Medical Research Center | Russia

Author Profile:

Scopus

Orcid

🏅 BEST RESEARCHER PROFILE: DR. YURIY BORSHCHEV

👨‍🎓 EARLY ACADEMIC PURSUITS

Dr. Yuriy Borshchev was born on April 13, 1968, in Chisinau, Republic of Moldova. His academic journey began at Chisinau State University, where he pursued his studies from 1985 to 1992 in the Faculty of Biology and Soil Science, majoring in Biology with a specialization in Human and Animal Physiology. This foundational education laid the groundwork for his future contributions to physiological and biomedical research.

💼 PROFESSIONAL ENDEAVORS

Before fully immersing himself in academia, Dr. Borshchev gained extensive practical experience in various industries. Between 1992 and 2007, he worked in mechanical engineering and food processing enterprises in Moldova, advancing from logistics roles to leadership positions such as enterprise director. In 2007, he transitioned into scientific research, joining the Pavlov Institute of Animal Physiology as a laboratory assistant and later as a research associate.

By 2012, he earned his PhD (Candidate of Biological Sciences) with a dissertation focused on the effects of probiotic bacteria on intestinal enzymes in rats with dysbiosis. His career progressed as he became a senior researcher at the Institute of Experimental Medicine and, later, the Almazov National Medical Research Center, where he now serves as Head of the Physiological Microendoecology Department.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON ISCHEMIC-REPERFUSION INJURY

Dr. Borshchev's work sits at the intersection of cardiology, gastroenterology, microbiology, and pathophysiology. His key contributions include:

  • Development of novel experimental biomedical models for studying inflammation and metabolic disorders.

  • Creation of a systemic inflammatory response model in rats, used to evaluate the therapeutic potential of probiotic bacteria.

  • Pioneering research into the influence of intestinal microbiota on myocardial resistance to ischemia-reperfusion injury.

  • Broad expertise in biochemical, histological, microbiological, and behavioral methodologies, as well as surgical experimentation on lab animals.

🌍 IMPACT AND INFLUENCE

Dr. Borshchev has significantly contributed to experimental medicine through:

  • Over 70 scientific publications, including 40 in SCI/SCIE journals and 18 indexed in Scopus/Web of Science/PubMed.

  • An H-index of 5, with a citation count of 22, reflecting ongoing recognition in specialized fields.

  • 8 completed research projects and 2 ongoing, amounting to over $800,000 USD in funding.

  • 5 industry-sponsored consultancy projects, demonstrating applied research impact.

  • Author and contributor to 8 books and proceedings with ISBNs.

  • One patent published, highlighting innovation in translational medical science.

📚 ACADEMIC CITES AND LEADERSHIP

In his academic and professional capacity, Dr. Borshchev:

  • Has served in editorial and reviewer roles for 2 journals/conferences.

  • Delivered 4 invited talks, attended 15 conferences, and visited 4 countries for international collaboration.

  • Supervised and graduated 2 research scholars, and is actively involved in collaborative scientific projects.

  • Maintains active profiles in global databases:

    • Scopus Author ID: 57206730176

    • Web of Science Researcher ID: IDE-1363-2014

    • elibrary.ru SPIN-code: 3454-4113

🧪 LEGACY AND FUTURE CONTRIBUTIONS

As a leading scientist at the Almazov National Medical Research Center, Dr. Borshchev continues to push the boundaries of experimental and translational medicine. His legacy is built on:

  • Bridging microbial ecology and systemic physiology.

  • Advancing knowledge in cardio-gastrointestinal interactions.

  • Training the next generation of scientists and building collaborative international partnerships.

Looking forward, Dr. Borshchev aims to expand his department's work into oncopharmacology and metabolic disease modeling, with the potential to influence both clinical therapies and preclinical standards.

🏆 AWARDS AND PROFESSIONAL AFFILIATIONS

Dr. Borshchev has been honored with 4 research awards, and holds 2 professional body memberships. He is committed to ethical research, demonstrated by his GLP-certified training in preclinical study protocols and laboratory animal handling.

🤝 COLLABORATIONS AND NETWORKING

  • 2 active MoUs with universities/industries.

  • 2 joint collaborative publications/projects.

  • Contributed to scientific communities across Russia, Europe, and other research-focused regions.

📌 CONCLUSION

Dr. Yuriy Borshchev exemplifies the qualities of a Best Researcher Award recipient: innovative, dedicated, and globally engaged. His work stands out for its relevance, depth, and potential to influence medical science well into the future.

📑 NOTABLE PUBLICATIONS

"Brain-Derived Neurotrophic Factor Cancels the Cardioprotective Effect of Interleukin-2 in a Model of Systemic Inflammatory Response in Rats"

Authors: I.Y., Burovenko, Inessa Yu , Y.Y., Borshchev, Yury Yu , S.M., Minasyan, Svetlana M. , ... O.V., Borshcheva, Olga V. , M.M., Galagudza, Mikhail M.
Journal: Bulletin of Experimental Biology and Medicine
Year: 2025

"Changes in the activity of amylase, alkaline phosphatase and lipase in placenta and umbilical cord blood in women in labor with gestational diabetes mellitus"

Authors: Elena V. Kolodkina; Sergey A. Lytaev; Michael M. Galagudza; Alexander B. Loginov; Tatyana M. Pervunina; Stanislav I. Sitkin; Yuri Yu. Borschchev; Olga V. Borschcheva
Journal: Medical academic journal
Year: 2025

Fengxu Yu | Atrial Fibrillation | Best Researcher Award 

Posted on by Pencis

Fengxu Yu | Atrial Fibrillation | Best Researcher Award 

The Affiliated Hospital of Southwest Medical University | China

Author Profile:

Scopus

👨‍⚕️ MR. FENGXU YU – PIONEER IN CARDIOVASCULAR INNOVATION

🎓 EARLY ACADEMIC PURSUITS

Born in January 1976, Professor Fengxu Yu embarked on his medical journey with a strong academic foundation, earning his M.D. and later achieving qualifications as a doctoral supervisor. His passion for cardiovascular science led him to pursue postdoctoral training in France, equipping him with a global perspective and refined clinical research skills. This international exposure laid the groundwork for his future leadership in complex cardiovascular research and surgical practice.

💼 PROFESSIONAL ENDEAVORS

Currently serving as a Professor at The Affiliated Hospital of Southwest Medical University, Dr. Yu holds several distinguished roles:

  • Standing Committee Member, Cardiac Surgery Committee (CAMEA)

  • Committee Member, Heart Valve Committee (CRHA)

  • Vice Chair, Sichuan Thoracic & Cardiac Surgery Association

  • Academic Leader, recognized by the Sichuan Health Commission

  • Member, Asian Heart Valve Society, China Chapter

  • Recipient, Luzhou Top Talent Award

His consistent dedication has cemented his role as a leading figure in thoracic and cardiac surgery across China.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON ATRIAL FIBRILLATION

Dr. Yu’s research endeavors focus on molecular and biomechanical mechanisms in cardiovascular disease, especially atrial fibrillation (AF), atherosclerosis, and aortic dissection. His current areas of exploration include:

  • Non-coding RNAs (e.g., circRNA/ceRNA networks) in AF pathogenesis

  • Application of induced pluripotent stem cells in modeling AF

  • Effects of shear stress on vascular endothelial health and its link to atherosclerosis

Through these efforts, Dr. Yu bridges basic science with clinical relevance, advancing the future of personalized medicine.

📊 IMPACT AND INFLUENCE

As a principal investigator, Dr. Yu has led nearly 20 major research projects funded by provincial and municipal institutions. He has also contributed to 30+ collaborative studies as a lead or co-investigator. His academic output includes over 50 peer-reviewed publications, with 12 articles indexed in SCI journals and 20+ papers in national core journals, showcasing his thought leadership in cardiovascular science.

📚 SELECTED RESEARCH PROJECTS

Some of Dr. Yu’s notable funded projects include:

  • Mechanism of Shear Stress-Downregulated Annexin A1 (2019)

  • circRNA-Regulated ceRNA Networks in AF (2025)

  • Personalized Warfarin Therapy Post-Valve Replacement (2022)

  • Hsa_circ_0025573—miR-133b—MMP9 in AF Pathogenesis (2022)

  • SRB1-Mediated Endothelial Injury in Atherosclerosis (2018)

These projects reflect a multidisciplinary approach to understanding and treating cardiovascular conditions.

🏅 ACADEMIC CITES AND MEMBERSHIPS

Professor Yu actively contributes to national and international academic bodies. His memberships include:

  • CAMEA – Cardiac Surgery Committee

  • CRHA – Heart Valve Committee

  • Sichuan Thoracic & Cardiac Surgery Association

  • Asian Heart Valve Society – China Chapter

These affiliations enhance his visibility in shaping future cardiac surgery standards and innovations.

🌟 LEGACY AND FUTURE CONTRIBUTIONS

Professor Fengxu Yu is a mentor, innovator, and academic leader. His mentorship of graduate students, collaboration with international institutions such as Heidelberg University, and continued work on translational research ensure a legacy of impactful science. As cardiovascular disease remains a global challenge, his pioneering work in non-coding RNA and biomechanical interactions is poised to redefine prevention and treatment strategies.

📑 NOTABLE PUBLICATIONS

"Myocardial infarction serum preconditioning bone marrow mesenchymal stem cell-derived exosomes enhance anti-fibrosis in rat myocardial infarction hearts" 

Authors: Y., Gan, Yang , C., Wang, Changyi , R., Liao, Ruili , ... H., Liu, Hui , Y., Fu, Yong
Journal: Molecular and Cellular Biochemistry.
Year: 2025

"Identification of the optimal reference genes for atrial fibrillation model established by iPSC-derived atrial myocytes" 

Authors: L., Li, Lei , Z., Zhao, Zijuan , Z., Liu, Zihao , ... Y., Nie, Yongmei , F., Yu, Fengxu
Journal: BMC Genomics
Year: 2024

"Postoperative delirium prediction after cardiac surgery using machine learning models" 

Authors: T., Yang, Tan , H., Yang, Hai , Y., Liu, Yan , ... Y., Zhang, Ying , F., Yu, Fengxu
Journal: Computers in Biology and Medicine
Year: 2024

Dongling Liu | TCM Pharmacology & Safety Research | Best Researcher Award

Posted on by Pencis

Prof. Dr. Dongling Liu | TCM Pharmacology & Safety Research | Best Researcher Award

Gansu University Of Chinese Medicine | China

Author Profile

Scopus

Google Scholar

🌟 PROF. DR. DONGLING LIU: A TRAILBLAZER IN CARDIOVASCULAR PHARMACOLOGY AND TCM INNOVATION

🎓 EARLY ACADEMIC PURSUITS

Professor Dongling Liu began her academic journey with a Bachelor of Science in Pharmacy from Lanzhou University (2003–2007). Driven by a passion for pharmacological research, she pursued her Master’s and Ph.D. in Microbial Pharmacy at the same university, completing her doctorate in 2013. These formative years laid the foundation for her expertise in cardiovascular pharmacology and traditional Chinese medicine (TCM).

👩‍🏫 PROFESSIONAL ENDEAVORS

In September 2013, Professor Liu joined the School of Pharmacy at Gansu University of Chinese Medicine, progressing through roles from Lecturer to Professor. She is also the Vice President of the Longyao Industrial Innovation Research Institute since December 2023. Her global exposure includes research stints as a Visiting Scholar at UC San Diego and Training at Sydney Medical School, which have broadened her scientific perspective and collaborative network.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON TCM PHARMACOLOGY & SAFETY RESEARCH

With a specialization in cardiovascular pharmacology, Professor Liu has led four NSFC projects, primarily exploring molecular mechanisms behind doxorubicin-induced cardiotoxicity and the cardioprotective effects of TCM compounds. Her team’s discovery on kaempferol’s inhibition of mitochondrial ROS-dependent ferroptosis has opened new avenues in drug development, bridging traditional medicine with modern pharmacological science.

📚 IMPACT AND INFLUENCE

Professor Liu’s academic impact includes 40+ publications, 10+ in SCI-indexed journals, and 24 indexed in Scopus/Web of Science/PubMed. Her cumulative impact factor over the last 3 years is 29.1, with an H-index of 8 (Scopus ID: 57216257824). She has also secured 4 patents (8 pending) and published a reference book.

🏆 ACADEMIC CITES AND RECOGNITION

Her research contributions have earned prestigious awards including the First Prize of Gansu Provincial Science & Technology Progress Award, the Huangfu Mi TCM Science Award, and recognition such as the Gansu Outstanding Youth Fund, Feitian Youth Scholar, and Longyuan Talent Award. She serves as a peer reviewer for NSFC and is a member of multiple national academic committees.

🌍 COLLABORATIONS, PROJECTS & EXTENSION WORK

Professor Liu has completed 5 research projects, is actively engaged in 3 ongoing projects, and has collaborated on 20+ national and regional grants. She has led 2 consultancy/industry-sponsored projects worth $300,000 USD, and maintains functional MoUs with 2 institutions. As an extension leader, she directed policy reforms and standardization of Gansu's proprietary “Longyao” TCM materials, trained farmers, and established a health product demonstration base.

🎤 CONFERENCES, TALKS AND EDITORIAL ROLES

She has presented at 20 conferences, delivered 10 invited talks, and organized 20 workshops and conferences. She holds 3 editorial appointments, reflecting her expertise and reputation in pharmacological research.

🎓 RESEARCH SCHOLAR DEVELOPMENT

To date, Professor Liu has mentored 8 research scholars to graduation and currently supervises 5 ongoing doctoral candidates, contributing significantly to the cultivation of future pharmacology experts.

🔮 LEGACY AND FUTURE CONTRIBUTIONS

Professor Liu is not only a distinguished educator and researcher but also a visionary in innovative TCM-based pharmacotherapy. Her ongoing efforts aim to integrate traditional Chinese formulations with modern therapeutic standards, thereby contributing to global healthcare innovation. Her work ensures a lasting legacy in cardiovascular pharmacology, policy reform, and rural health development.

📑 NOTABLE PUBLICATIONS

"Exploring the efficacy and mechanism of Qingxuan decoction in treating opioid-induced constipation" 

Authors: Y., Zhang, Yarong , H., Cao, Haoshi , L., Su, Linling , ... D., Liu, Dongling , Y., Hai, Yang
Journal: Pharmacological Research - Modern Chinese Medicine
Year: 2025

"Effect of shenmai injection on anthracycline-induced cardiotoxicity: A systematic review and meta-analysis" 

Authors: Lili Yang, Xiaorui Liu,  Wen Yang,  Siqi Wang,  Zimu Li,  Yiming Lei,  Dongling Liu
Journal: Health Sciences
Year: 2024

Xu Zhichen | Esophageal Cancer | Best Research Article Award

Posted on by Pencis

Dr. Xu Zhichen | Esophageal Cancer | Best Research Article Award

First Hospital of Quanzhou Affiliated to Fujian Medical University | China

Author Profile:

Scopus

👨‍⚕️ XU ZHICHEN: DEDICATED HEALER AND ESOPHAGEAL CANCER RESEARCHER

📚 EARLY ACADEMIC PURSUITS

Xu Zhichen was born in Putian, belonging to the Han ethnic group. His journey into the world of medicine began with a Bachelor's degree in Clinical Neurology from Luzhou Medical College (2005–2010). Demonstrating a strong passion for advancing cancer treatment, he pursued a Master’s degree in Radiation Oncology at Fujian Medical University (2010–2013), focusing on Radiotherapy. His formal education laid a solid foundation for a career devoted to battling cancer, particularly esophageal cancer.

🏥 PROFESSIONAL ENDEAVORS

Following his master’s program, Xu Zhichen completed standardized clinical training at Quanzhou First Hospital (2013.9–2014.9). In September 2014, he officially joined the Radiotherapy Department at the same institution, where he continues to serve with distinction as an Associate Chief Physician. His dedication and skill have earned him certifications at every level of practice, including:

  • Practicing Physician Certificate (2016)

  • Official Appointment (2018)

  • Vice Senior Certification in Radiotherapy (2024)

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON ESOPHAGEAL CANCER

Dr. Xu Zhichen is a recognized specialist in esophageal cancer, with his clinical and research efforts focusing on radiotherapy advancements. His notable academic contributions include:

  • Leading one provincial and one municipal research project.

  • Publishing 1 CSCD-indexed paper, 2 SCI-indexed papers, and multiple provincial-level papers.

These publications highlight his continuous effort to innovate and improve therapeutic strategies in radiation oncology.

🌐 IMPACT AND INFLUENCE

Dr. Xu’s influence extends beyond the clinic. He is a prominent figure in academic and professional circles:

  • Selected for the "Hundred Talent Program" at Quanzhou First Hospital – a mark of distinction for emerging medical leaders.

  • Serves as a Member of the Youth Committee of the Fujian Radiation Oncology Society, where he contributes to shaping policies and mentoring young oncologists.

📊 ACADEMIC CITES AND RECOGNITION

Though still in the early stages of senior-level research contribution, Dr. Xu’s SCI and CSCD publications have gained attention in the oncology community. His work is regularly cited in Chinese medical journals focused on radiotherapy protocols and esophageal cancer treatment methodologies, underlining his growing academic footprint.

🌟 LEGACY AND FUTURE CONTRIBUTIONS

With a decade of focused clinical experience and increasing research output, Dr. Xu Zhichen is set to become a leading voice in radiation oncology in Fujian Province and beyond. His blend of practical excellence, academic commitment, and institutional leadership signals a promising trajectory. Future expectations include:

  • Expansion into multi-institutional clinical trials on esophageal cancer.

  • Publishing in high-impact international journals.

  • Training and mentoring the next generation of radiation oncologists.

📑 NOTABLE PUBLICATIONS

"A dynamic nomogram for predicting abdominal lymph node recurrence in patients with esophageal carcinoma" 

Authors: Z., Xu, Zhichen , B., Su, Baoan , M., Lin, Mingqiang , Q., Xu, Qinghua , M., Qu, Mengke
Journal: Scientific Reports
Year: 2025

Heng Zhang | Cardiology | Best Researcher Award

Posted on by Pencis

Dr. Heng Zhang | Cardiology | Best Researcher Award

Fuwai Hospital, National Center for Cardiovascular Diseases | China

Author Profile

Scopus

Orcid ID

HENG ZHANG, M.D., PH.D. 🩺🫀

Dr. Heng Zhang is a distinguished medical professional specializing in cardiovascular surgery, with substantial contributions to the field of cardiovascular disease research, clinical practice, and health innovation. Holding a dual degree in medicine (M.D.) and a doctorate in philosophy (Ph.D.), Dr. Zhang’s academic and professional endeavors continue to shape the landscape of modern cardiovascular surgery, offering valuable insights into risk prediction, coronary revascularization, and the optimization of treatment strategies for cardiovascular diseases. His current role as an Associate Chief Physician at Fuwai Hospital, National Clinical Research Center of Cardiovascular Diseases, further cements his impact on the advancement of medical science.

EARLY ACADEMIC PURSUITS 🎓

Dr. Heng Zhang's academic journey began with an M.D. degree from Tianjin Medical University, where he graduated in 2010. During his studies, Dr. Zhang displayed a keen interest in cardiovascular health, which led him to pursue a Ph.D. in Cardiovascular Disease from Peking Union Medical College in 2015. Throughout his academic path, he also participated in key research exchanges, including a Visiting Scholar program in the USA at Duke Clinical Research Institute, further broadening his expertise in cardiovascular outcomes research and clinical performance measures.

PROFESSIONAL ENDEAVORS 👨‍⚕️🏥

Dr. Zhang’s clinical training began in 2009 with an internship at Nankai Hospital and continued through various stages of residency, including Peking Union Medical College Hospital and Fuwai Hospital. By 2015, he began specializing in cardiovascular surgery, eventually becoming an Attending Physician at Fuwai Hospital in 2019. His extensive clinical exposure includes pediatric and adult cardiac surgery, where he gained invaluable experience in treating complex heart conditions and improving patient outcomes through innovative surgical techniques.

CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOLOGY🔬💡

Dr. Zhang’s research has primarily focused on cardiovascular surgery registry, coronary revascularization risk prediction, and optimizing diagnostic and treatment strategies for cardiovascular conditions. He is deeply engaged in cardiovascular outcomes research, with particular attention to improving clinical performance measures and treatment protocols for heart diseases.

As the principal investigator and host of multiple high-impact research projects, Dr. Zhang has led groundbreaking studies such as evaluating the efficacy and safety of RN medications in preventing myocardial injury caused by ischemia-reperfusion and examining macrophage subtypes in coronary atherosclerosis. He has also significantly contributed to understanding valve replacement surgery and the long-term effects of heart valve interventions.

IMPACT AND INFLUENCE 🌍💪

Dr. Zhang's contributions to cardiovascular medicine have left a profound mark on clinical practice and research. Through his involvement in various research grants, including National Key Research and Development Plans of China and the Natural Science Foundation of China, Dr. Zhang has been pivotal in advancing both the theoretical and practical aspects of cardiovascular disease treatment and prevention. His work has also led to a shift in how cardiovascular surgeries are approached, particularly regarding patient-specific interventions in coronary artery malformation and atrial fibrillation.

His research projects have earned him several prestigious accolades, such as the Outstanding Reviewer for the Chinese Clinical Journal of Thoracic and Cardiovascular Surgery and the American Heart Association Travel Stipend Award. Dr. Zhang’s clinical and academic contributions are shaping future medical protocols, paving the way for a more personalized approach to heart disease treatment.

ACADEMIC CITES & HONORS 🏅📚

Dr. Zhang’s academic excellence is reflected not only in his research citations but also in the numerous honors and scholarships he has received. These include multiple first prizes for Young Investigator Awards, outstanding doctoral dissertations, and recognitions for clinical excellence. His impressive list of awards, including the Beijing Science and Technology Award (2016) and the Outstanding Doctoral Dissertation from Peking Union Medical College (2016), highlights his leadership and commitment to medical innovation.

LEGACY AND FUTURE CONTRIBUTIONS 🔮🏅

Dr. Zhang’s legacy lies in his consistent drive to innovate and advance cardiovascular surgery. His work with various research institutions and medical centers has laid a robust foundation for the continued improvement of heart disease diagnosis and treatment. As a principal investigator for several key projects and his role on editorial boards such as the Journal of American Heart Association, Dr. Zhang is poised to influence future cardiovascular research and practice for years to come.

Looking ahead, his research into heart valve replacement and atrial fibrillation is expected to lead to new clinical strategies that will enhance patient care globally. His future contributions are expected to redefine approaches to cardiovascular health, with an emphasis on personalized medicine and novel surgical techniques.

FINAL THOUGHTS 🧠💖

Dr. Heng Zhang is a leading figure in cardiovascular medicine, combining clinical expertise with cutting-edge research to make significant advancements in heart disease treatment. His future is one of continued excellence and innovation, as he works tirelessly to shape the future of cardiovascular care, improving the lives of patients worldwide.

NOTABLE PUBLICATIONS 📑

"Impact of remnant cholesterol on short-term and long-term prognosis in patients with prediabetes or diabetes undergoing coronary artery bypass grafting: a large-scale cohort study" 

  • Authors: Z., Li, Zhongchen , C., Yu, Chunyu , H., Zhang, Heng , Y., Zhao, Yan , Z., Zheng, Zhe
  • Journal: Cardiovascular Diabetology
  • Year: 2025

"Association of stress hyperglycemia ratio with short-term and long-term prognosis in patients undergoing coronary artery bypass grafting across different glucose metabolism states: a large-scale cohort study" 

  • Authors: Z., Li, Zhongchen , R., Chen, Runze , Z., Zeng, Zhiwei , H., Zhang, Heng , Z., Zheng, Zhe
  • Journal: Cardiovascular Diabetology
  • Year: 2025

"Clinical Outcomes of Surgical Revascularization Strategies Guided by Quantitative Flow Ratio in Primary Noncoronary Cardiac Surgery" 

  • Authors: L., Li, Linlin , H., Zhang, Heng , C., Rao, Chenfei , C., Liu, Chang , H., Fan, Hongguang
  • Journal: Journal of Thoracic Imaging
  • Year: 2024

"Association of carotid duplex ultrasonography screening with stroke and mortality among patients undergoing coronary artery bypass grafting" 

  • Authors: H., Zhang, Heng , D., Zhang, Danwei , J., Qu, Jianyu , X., Qian, Xiangyang , Z., Zheng, Zhe
  • Journal: Journal of Vascular Surgery
  • Year: 2024

"Impact of High Lipoprotein(a) on Long-Term Survival Following Coronary Artery Bypass Grafting" 

  • Authors: S., Yuan, Shuo , F., Li, Fangzhou , H., Zhang, Heng , Y., Zhao, Yan , Z., Zheng, Zhe
  • Journal: Journal of the American Heart Association
  • Year: 2024